A company focused on treating underserved patients announced that the first patient with an NTRK fusion was dosed in a phase 2 trial of taletrectinib this summer.
AnHeart Therapeutics Co., Ltd. Announced in late June that it had dosed the first patient in a phase 2 trial of taletrectinib for solid tumors containing NTRK fusions. The trial is built upon promising results seen in a phase 2 trial for non-small cell lung cancer (NSCLC) with ROS1 fusions.
The researchers plan to enroll 40 patients in China in the single-arm trial. AnHeart entered into an agreement with Innovent Biologics, Inc. in June in which Innovent will co-develop and commercialize taletrectinib in Greater China.
“Many patients with rare conditions, like NTRK fusion-positive cancer have limited treatment options and poor access to targeted therapies,” said Dr. Hui Zhou, senior vice president of clinical development at Innovent, in a release. “We are very pleased to see that our partner AnHeart is advancing the Phase II trial of taletrectinib in NTRK fusion-driven solid tumors. We will work closely with AnHeart to bring taletrectinib to patients in Greater China.”
Taletrectinib is an investigational TKI that targets ROS1 and NTRK. It has potential to treat TKI-naïve or pretreated patients.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.